Anti-p14ARF (p19ARF)

32160702

Tumor suppressor ARF (UniProt Q8N726; also known as Alternative reading frame, ARF, Cyclin-dependent kinase inhibitor 2A, p14ARF, p19ARF) is encoded by the CDKN2A (also known as CDKN2, MLM) gene (Gene ID 1029) in human. p14ARF acts as a tumor suppressor and a key regulator of cellular proliferation that is frequently inactivated in human cancers. It binds to MDM2 and blocks its oncogenic action by inhibiting MDM2-induced degradation of p53. Reported to form a ternary complex with p120(E4F) and p53 that enhances p14ARF-induced G2 cell cycle arrest in a p53-dependent manner. However, it can also induce G2 arrest and apoptosis in a p-53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to E2F1 and MYC and blocks their transcriptional activator activity without affecting MYC transcriptional repression. Human p14ARF is shown to promote the proteasomal degradation of Melanoma antigen-A11 (MAGE-A11) independent of HDM2 E3 ubiquitin ligase or lysine ubiquitination. It inhibits the ability of MAGE-A11 to stabilize and stimulate androgen receptor (AR) or E2F1 transcriptional activity. Ref.: Minges, JT et al. (2015). J. Biol. Chem. 290, 25174-25187. Rizos, H., et al. (2003). J. Biol. Chem. 278, 4981-4989.

This rabbit polyclonal antibody targets the C-terminal end sequence present in both ARF spliced isoforms, p14ARF (p19ARF) and smARF, reported by UniProt (Q8N726). This polyclonal antibody does not detect the INK4 spliced isoforms (UniProt P42771) also encoded by the CDKN2A gene.

KLH-conjugated linear peptide corresponding to human p14ARF (p19ARF)/smARF C-terminal end sequence.
Epitope: C-terminus

Detect tumor suppressor ARF using this rabbit polyclonal Anti-p14ARF (p19ARF), Cat. No. ABC1430, validated for use in Immunohistochemistry, Immunoprecipitation, and Western Blotting.
Research Category
Apoptosis & Cancer
Immunohistochemistry Analysis: A representative lot detected p14ARF (p19ARF) immunoreactivity in formalin-fxed, paraffin-embedded human lung tissue sections. An upregulated p14ARF (p19ARF) immunoreactivitiy was found in a lung tissue with squamous cell carcinoma when compared to a normal lung tissue sample (Vonlanthen, S., et al. 1998. Oncogene. 17(21):2779-2785).

Immunoprecipitation Analysis: A representative lot co-immunoprecipitated MDM2 and p53 with p14ARF (p19ARF) either from HeLa cells transfected to overexpress the three proteins or from in vitro transcription/translation reactions (Zhang, Y., et al. 1998. Cell. 92(6):725-234).

Western Blotting Analysis: Representative lots detected HA-tagged human p14ARF (p19ARF) exogenously expressed in HeLa and COS-7 cells, but not in untransfected K562 cells (Vonlanthen, S., et al. 1998. Oncogene. 17(21):2779-2785; Zhang, Y., et al. 1998. Cell. 92(6):725-234).

Evaluated by Western Blotting in PC3 cell lysate.

Western Blotting Analysis: A 1:2,000 dilution of this antibody detected p14ARF (p19ARF) in 10 µg of PC3 human prostate cancer cell lysate.

Affinity purified.
Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Concentration: Please refer to lot specific datasheet.

rabbit

100

affinity isolated antibody

primary antibodies

polyclonal

affinity chromatography

human

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

NP_478102

Q8N726

ambient

~17 kDa observed. 13.90 kDa (p14ARF or p19ARF) and 8.731 kDa (smARF) calculated. Uncharacterized bands may be observed in some lysate(s).

Stable for 1 year at 2-8°C from date of receipt.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 1